Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 7/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | CPT2 | P23786 | 3/20 | 0.39 |
| ▸ | CPT1A | P50416 | 3/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 2/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19364891 | 0.91 | MCHR1 (0.42) | MCHR1HDAC2CPT2CPT1AGRM5 | |
| SCHEMBL19670520 | 0.90 | CPT1A (0.37) | MCHR1HDAC2CPT1AATR | |
| SCHEMBL19365297 | 0.89 | HDAC2 (0.41) | MCHR1HDAC2CPT2CPT1ACPT1B | |
| SCHEMBL19703381 | 0.87 | GRM5 (0.42) | MCHR1GRM5ATR | |
| SCHEMBL19365428 | 0.86 | HDAC2 (0.48) | MCHR1HDAC2CPT2CPT1ACPT1B | |
| SCHEMBL19365747 | 0.86 | MCHR1 (0.41) | MCHR1HDAC2CPT2CPT1ACPT1B | |
| SCHEMBL19365374 | 0.86 | MCHR1 (0.41) | MCHR1HDAC2CPT2CPT1ACPT1B | |
| SCHEMBL19365606 | 0.86 | ATR (0.48) | HDAC2CPT2CPT1ACPT1BATR | |
| SCHEMBL19670421 | 0.85 | MPL (0.44) | MCHR1CPT2CPT1ACPT1BATR | |
| SCHEMBL19364819 | 0.85 | MCHR1 (0.47) | MCHR1HDAC2ATRPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | MCHR1 4256/4885HDAC2 50/4885CPT2 56/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | MCHR1 4256/4885HDAC2 50/4885CPT2 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.